Hydrocortisone (Efmody^®) is recommended as an option for restricted use within NHS Wales.

Hydrocortisone (Efmody^®) is licensed for the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and older and in adults.

Hydrocortisone (Efmody^®) is restricted for use as a second-line treatment option in adolescents not adequately controlled on maximum guideline doses of immediate-release hydrocortisone; and as a third-line treatment in adults not adequately controlled on maximum guideline doses of immediate-release hydrocortisone and/or prednisolone.

Hydrocortisone (Efmody^®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.